Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLAT-03: CD19t T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia
NCT03186118Phase 1Active, not recruiting
- Sponsor
- Seattle Children's
- Start
- Aug 2017
- Primary completion
- Sep 2021
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD19t T-APC in acute leukemia (4 cohorts), sponsored by Seattle Children's. Primary endpoints: Adverse events associated with one or multiple CD19t T-APC product infusions at 6 months and Feasibility of deriving and administering a CD19t T-APC product at 28 days. Started Aug 2017; status: active, not recruiting.
02
Drugs
CD19t T-APC
03
Conditions
acute leukemia
Beyond the preview
Go deeper on NCT03186118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03186118.